NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the "Company" or "HSAC 2") announced today that it priced its initial public offering of 13,913,044 ordinary shares at $10.00 per share. The sponsor of the Company is HSAC 2 Holdings, LLC, an affiliate of RTW Investments, LP. The ordinary shares are expected to be listed on The Nasdaq Capital Market ("Nasdaq") and trade under the ticker symbol "HSAQ" beginning today, August 4, 2020. The offering is expected to close on August 6, 2020, subject to customary closing conditions.
The Company is led by Chairman and CEO Roderick Wong MD, and CFO Naveen Yalamanchi, MD. The Company is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry. It is the Company's intention to pursue prospective targets that are focused on biopharmaceutical and medical technology innovation. The proceeds of the offering will be used to fund such business combination.
Chardan and Barclays acted as joint book running managers in the offering. The underwriters have been granted a 45-day option to purchase up to an additional 2,086,956 ordinary shares offered by the Company to cover over-allotments, if any, at the initial public offering price.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 3, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Health Sciences Acquisitions Corporation 2
Health Sciences Acquisitions Corporation 2 is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Health Sciences Acquisitions Corporation 2 anticipates targeting companies domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors, which aligns with our management team's experience in healthcare investing and drug development.
Forward Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of the Company's initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
|
Contact:
|
Stephanie A. Sirota
|
|
Vice President of Corporate Strategy and Corporate Communications of HSAC 2
|
|
sas@rtwfunds.com
|
View original content:http://www.prnewswire.com/news-releases/health-sciences-acquisitions-corporation-2-announces-pricing-of-upsized-139-1-million-initial-public-offering-301105569.html
SOURCE Health Sciences Acquisitions Corporation 2